Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology
GlaxoSmithKline Biologicals S.A.
J07
Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E
Vaccines
Respiratory Syncytial Virus Infections
Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older.The use of this vaccine should be in accordance with official recommendations.
Authorised
2023-06-06
20 B. PACKAGE LEAFLET 21 PACKAGE LEAFLET: INFORMATION FOR THE USER AREXVY POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU RECEIVE THIS VACCINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Arexvy is and what it is used for 2. What you need to know before you receive Arexvy 3. How Arexvy is given 4. Possible side effects 5. How to store Arexvy 6. Contents of the pack and other information 1. WHAT AREXVY IS AND WHAT IT IS USED FOR Arexvy is a vaccine that helps to protect adults aged 60 years and older against a virus called ‘respiratory syncytial virus’ (RSV). RSV is a respiratory virus that spreads very easily. RSV can cause lower respiratory tract disease - infections of the lungs and other parts of the body that help you breathe. RSV infection can happen at any age, and usually causes mild, cold-like signs in adults. But it can also: cause more serious respiratory illness in infants and older adults make some illnesses worse, such as long-term respiratory or heart diseases. HOW AREXVY WORKS Arexvy helps your body’s natural defences make antibodies and special white blood cells. These protect you against RSV. Arexvy does not contain the virus. This means it cannot cause an infection. 2. WHAT YOU NEED TO KNOW BEFORE YOU RECEIVE AREXVY DO NOT USE AREXVY if you are alle Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, one dose (0.5 mL) contains: RSVPreF3 1 antigen 2,3 120 micrograms 1 Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3 2 RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology 3 adjuvanted with AS01 E containing: plant extract _Quillaja saponaria_ Molina, fraction 21 (QS-21) 25 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from _Salmonella minnesota_ 25 micrograms For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and suspension for suspension for injection. The powder is white. The suspension is an opalescent, colourless to pale brownish liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older. The use of this vaccine should be in accordance with official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Arexvy is administered as a single dose of 0.5 mL. The need for revaccination with a subsequent dose has not been established. _Paediatric population _ The safety and efficacy of Arexvy in children have not been established. No data are available. 3 Method of administration For intramuscular injection only, preferably in the deltoid muscle. For instructions on reconstitution of the medicinal product before administration, see section 6.6. 4.3 CONTRAINDICATIONS Hypersensitivi Lue koko asiakirja